The phase 3 SIENDO trial, examining the use of frontline maintenance selinexor after combination chemotherapy in patients with advanced or recurrent endometrial cancer, met its primary end point of a statistically significant improvement in progression-free survival.
Research from a 2-part, phase 2 trial found that ibrutinib and rituximab followed by hyper-fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone produced positive response data and a manageable safety profile for younger patients with mantle cell lymphoma.
Zev A. Wainberg, MD, discusses future research efforts for the treatment of patients with advanced gastric cancer.
Consolidation therapy with bortezomib, lenalidomide, and dexamethasone plus lenalidomide maintenance improved progression-free survival in patients with newly diagnosed multiple myeloma.
PDS Biotechnology Corporation announced that the combination of PDS0101 and pembrolizumab achieved preliminary response efficacy for patients with advanced human papillomavirus–associated head and neck cancer.
Patients with HER2-positive breast cancer who were treated with trastuzumab deruxtecan experienced favorable activity and reduction or loss of HER2 expression.
A cohort study found that immune-mediated diseases were associated with a higher increased risk of total cancer, and organ-specific immune-mediated diseases were more strongly associated with local cancers than extra-local cancers.
Researchers prospectively analyzed the effect of implementing systemic outpatient identification on initiating goals of care conversations for high-risk patients with gynecologic cancers.
Alicia Morgans, MD, discusses genomic testing and use of PARP inhibitors for metastatic castration-resistant prostate cancer.
Ghassan K. Abou-Alfa, MD, detailed the evolution of treatment options for unresectable hepatocellular carcinoma prior to the phase 3 HIMALAYA study and the reasons for launching the trial.
Patients with PD-1/PD-L1–refractory metastatic non–small cell lung cancer did not achieve additional benefit when radiotherapy was added to durvalumab and tremelimumab.
John Kirkwood, MD, PhD, discusses the use of immunotherapy as a treatment option for melanoma, including ctDNA, and how to properly monitor responses.
In recognition of World Cancer Day, Daniel Vorobiof, MD, touched on the use of Belong.life, a patient-centric social and professional network, in collecting real-world data and providing patients with additional resources, and highlighted several real-world data studies that were conducted with the application’s data.
According to a study conducted at a single cancer center in Southern Maryland, patients who survived breast or prostate cancer were less likely to receive a colorectal cancer screening.
The 2021 United States Preventive Services Task Force lung cancer screening criteria changes successfully reduced racial disparities in eligibility by broadening screening eligibility criteria.
In recognition of World Cancer Day, CancerNetwork® spotlights NCCN efforts to reduce disparities in cervical cancer.
For World Cancer Day, CancerNetwork® reviews key highlights from the Cancer Facts & Figures 2022 report from the American Cancer Society, with updates in cancer incidence, mortality, and survival across patient subgroups.
Experts explored existing data to create a universal definition of integrative oncology, in tandem with feedback from Society of Integrative Oncology, to better explains what the term means.
Abiraterone acetate and luteinizing hormone–releasing hormone agonist is a promising second-line option for androgen receptor–expressing castration resistant salivary gland cancer.
Umbralisib is currently under investigation by the FDA regarding a potentially increased risk of death in patients with lymphomas following data from an ongoing trial investigating its use in chronic lymphocytic leukemia.
Despite universal recommendations for genetic testing, data indicate that the use of germline testing remained underused among women with ovarian cancer who had commercial insurance.
Michael R. Bishop, MD, discussed details from the ZUMA-7 and TRANSFORM trials that were presented at the 63rd ASH Annual Meeting.
Michael R. Bishop, MD, highlighted the population of patients with relapsed/refractory B-cell non-Hodgkin lymphoma who were enrolled on the phase 3 BELINDA study and treated with tisagenlecleucel.
Breast cancer risk was estimated among survivors of pediatric cancer who were treated with chest radiation with a newly developed and validated breast cancer risk prediction model.
Prescription of an appropriate duration of antivirals for the prevention of Varicella-Zoster virus reactivation in patients with multiple myeloma has notable importance, with experts emphasizing a need to adhere to treatment guidelines.
Patients with metastatic cutaneous squamous cell carcinoma who were treated with cosibelimab experienced a positive objective response rate.
Due to an imbalance of investigator-reported unexpected adverse reactions, the FDA placed a partial clinical hold on all trials examining the combination of magrolimab and azacitidine in acute myeloid leukemia and myelodysplastic syndrome.
The FDA has placed a partial clinical hold on trials using umbralisib and ublituximab as a treatment for chronic lymphocytic leukemia and non-Hodgkin lymphoma.
CUE-101 could be a potentially promising therapeutic agent for patients with recurrent/metastatic, HPV16-positive head and neck squamous cell carcinoma.
A new drug application for parsaclisib to treat relapsed/refractory mantle cell lymphoma, marginal zone lymphoma, and follicular lymphoma has been withdrawn.
